Skip to main content

Table 1 Clinical characteristics of the study cohort

From: Bone histomorphometric changes in children with rheumatic disorders on chronic glucocorticoids

Clinical variable Results (n = 15)
Age at time of bone biopsy (years) 14.0 ± 3.2
Age at diagnosis of rheumatologic disease (years) 7.6 ± 3.6
Anthropometry at time of bone biopsy
 Height Z score −2.3 ± 1.4
 Weight Z score −0.2 ± 1.4
 Body mass index Z score 0.8 ± 1.2
 Pubertal stage (% of subjects pre-pubertal: mid-pubertal: post-pubertal)b 33:40:27
Rheumatic condition characteristics
 Functional ability at time of bone biopsy (CHAQ score) 0.25 (0 to 1.87)a
 Erythrocyte sedimentation rate (mm/h) 13 (1 to 57)a
Glucocorticoid treatment
 Duration of glucocorticoid treatment (years) 6.2 ± 4.1
 Cumulative glucocorticoid dose (mg/m2)c 29134 ± 29410
 Average glucocorticoid dose (mg/m2/day)c 14.1 ± 6.2
Number of vertebral fractures (number of subjects)
 1 vertebral fracture 5 (33 %)
 2 to 4 vertebral fractures 3 (20 %)
  ≥ 5 vertebral fractures 7 (47 %)
Fracture severity (number of subjects)d
 Grade 1 3 (20 %)
 Grade 2 10 (67 %)
 Grade 3 2 (13 %)
Lumbar spine areal BMD Z score −3.4 (−5.5 to −1.7)a
Lumbar spine BMAD Z score −2.9 (−4.1 to −0.9)a
Serum 25(OH)D (nmol/L) 69.5 (43 to 118)a
  1. Results are expressed as mean ± standard deviation unless otherwise indicated
  2. amedian (range)
  3. bpre-pubertal: Tanner stage 1, mid-pubertal: Tanner stage 2 and 3, post-pubertal: Tanner stage 4 and 5
  4. creported in prednisone equivalents
  5. dpatients with multiple vertebral fractures were graded according to the highest severity score